

**Minutes of the meeting of the AREA PRESCRIBING COMMITTEE held on
Wednesday 14th September 2016 in the Boardroom at Hilder House**

MEMBERS:

Dr M Ghani (Chair up to 16/176)	Medical Director (Barnsley CCG)
Ms C Lawson (Chair from 16/176)	Head of Medicines Optimisation (Barnsley CCG)
Ms D Bailey	Interim Head of Quality for Primary Care (Barnsley CCG)
Mr T Bisset	Community Pharmacist (LPC)
Dr R Hirst	Palliative Care Consultant (Barnsley Hospice)
Dr J Maters	General Practitioner (LMC)
Dr A Munzar	General Practitioner (LMC)
Ms J Riley	Chief Pharmacist (SWYPFT)
Mr M Smith	Chief Pharmacist (BHNFT)

ATTENDEES:

Ms C Applebee	Medicines Management Pharmacist (Barnsley CCG)
Ms N Brazier	Administration Officer (Barnsley CCG)
Mr N Heslop	Lead Pharmacist (Barnsley CCG)
Mr F Hussain	Senior Interface Pharmacist (BHNFT)
Ms G Turrell	Lead Pharmacist, Medicines Information (BHNFT)

APOLOGIES:

Ms S Hudson	Lead Pharmacist (SWYPFT)
Dr R Jenkins	Medical Director (BHNFT)
Dr K Kapur	Consultant Gastroenterology (BHNFT)
Dr K Sands	Associate Medical Director (SWYPFT)

**ACTION BY
AND
DEADLINE**

APC 16/165 QUORACY – the meeting was quorate.

APC 16/166 DECLARATIONS OF INTEREST – no declarations of interest to note.

APC 16/167 MINUTES OF 10 AUGUST 2016 MEETING – approved.

APC 16/168 MATTERS ARISING AND APC ACTION PLAN

168.1 NICE TA's (June 2016)

- NICE TA396 Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma – **not applicable for use at BHNFT**

168.2 NICE TA's (July 2016)

Awaiting feedback for the following NICE TAs: -

- TA259 updated (from June 2012) - Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen
- TA387 updated - Abiraterone for treating metastatic

hormone-relapsed prostate cancer before chemotherapy is indicated

- TA400 - Nivolumab in combination with ipilimumab for treating advanced melanoma

Agreed action

- Feedback to be provided at the October 2016 APC meeting.

GT

168.3

Continence and Urology Service – audit on compliance to prescribing guidelines

There has been email communication outside of the meeting and the service has been asked to provide background information to the APC to support the audit previously submitted.

Agreed actions:-

- The Head of Medicines Optimisation to forward email communications to the Chief Pharmacist, SWYPFT to help her follow up progress with the Lead Pharmacist, SWYPFT
- Chief Pharmacist, SWYPFT to follow this up with Lead Pharmacist, SWYPFT and the service to be advised that links to the algorithm on the BEST website be included in the letters sent out to GPs

CL

JR/SH

168.4

Physeptone

Following discussions at the last meeting, indications from emails in circulation were that this change had been completed. A letter has been drafted asking BMBC representative to attend the APC. The GP member (JM) noted that primary care have not been informed of this change.

It was noted that the substance misuse service was currently out to national tender and from the 1 April 2017 there may be a new provider. It would be important to ensure that service links and service delivery commitments with the CCG and APC are clarified within the new arrangements.

Agreed actions

- The Head of Medicines Optimisation, Barnsley CCG to write to the current providers to invite them to attend the APC meeting to address the concerns raised by the Committee, reminding them that as a member of the Committee, they have a duty and responsibility to present potential formulary changes to the Committee for consideration as the Committee make decisions on behalf of the whole locality.
- The Head of Medicines Optimisation to write to Helen Norton, who is leading on the procurement, with the Committee's comments to ensure that the new provider going forward either reverses the decision or does not make any further decisions without consulting with the Committee in the first instance

CL

CL

168.5	<p><u>Action Plan – Other Areas</u> <u>Co-amoxiclav secondary care guidance</u> Agreed action: - The Lead Pharmacist to: -</p> <ul style="list-style-type: none"> • Present quarter 2 figures to the next meeting and present comparative data. GT • Discuss the actions with the microbiologists and escalate to Dr Jenkins at the next Medicines Management meeting (15.09.16) to help reduce co-amoxiclav prescribing. GT <p>The Chair of the APC would provide support if required to ensure progress is made.</p>
168.6	<p><u>Discharge Letter Audit</u> The Chair provided an update following the Quality Review Meeting between the Trust and the CCG held in August 2016. The Trust has an action plan in place and is communicating with the CCG. The Trust and CCG agreed to: -</p> <ul style="list-style-type: none"> • Redesign the D1 then roll it out • Trust to re-audit in February 2017 <p>There were ongoing discussions about the value and use of Summary Care Records and the Trust were to review the audit criteria.</p> <p>The Lead Pharmacist, BHNFT confirmed that in terms of medicines reconciliation, they do use Summary Care Records but as a rule use at least 2 information sources.</p> <p>Agreed action</p> <ul style="list-style-type: none"> • Following a discussion about the current medication list, it was agreed that the Lead Pharmacist, BHNFT would map this against the redesigned D1. GT
APC 16/169	<p>APG REGIONAL CONSULTATION A consultation has been issued to consider the core purpose, operational governance arrangements, committee membership and work plan allocation and the status of outputs from the committee. The Committee are invited to respond to these proposals generally, and/or on specific aspects.</p> <p>Agreed actions</p> <ul style="list-style-type: none"> • The Head of Medicines Optimisation to circulate details of the consultation to Committee members CL 14.09.16 • Committee members to return any comments to the Head of Medicines Optimisation by 18th September 2016 ALL 18.09.16 • The Head of Medicines Optimisation to collate responses, share the draft response with the Chair and respond by 19th September 2016 on behalf of the APC CL 19.09.16
APC 16/170	<p>PALLIATIVE CARE FORMULARY Agreed actions</p> <ul style="list-style-type: none"> • Committee members to feed back any further comments to the Palliative Care Consultant (Barnsley Hospice). ALL

- The Community Pharmacist to share the link to the LPC website for inclusion in the formulary, which lists the pharmacies that offer the specialist drugs on demand
- It was requested that the final version be presented in the post graduate department and be made accessible to GPs on the ward and to support with training.
- A copy of the final version to be sent to the Medicines Management Pharmacist, Barnsley CCG

TB
RH
RH

It was agreed that with these amendments that the formulary was endorsed.

APC 16/171 RESPIRATORY FORMULARY REVIEW (SWITCH FROM EPIPEN TO EMERADE PENS)

In relation to the agreed switch from Epipens to Emerade pens as part of the respiratory formulary review in June 2016, a response from Dr Kerrin, Consultant Paediatrician and Allergy Lead, BHNFT had been received who wanted to recommend the continued use of Epipens.

Agreed action: -

- Following discussion, the Committee agreed to invite Dr Kerrin to the October 2016 APC meeting to discuss the devices further to allow him to put forward his reasonable objections from his expertise.
- Declaration of interest form to be completed and returned by Dr Kerrin prior to attendance at the October 2016 APC meeting

GT
NB/GT

APC 16/172 SHARED CARE GUIDELINES

In relation to the future contracting changes around Share Care – Chris that communicate with Helen Norton and that Dr Ghani would also be copied into any correspondence.

CL

172.1 Naltrexone Shared Care Guidelines

The Naltrexone Shared Care Guideline has been reviewed and updated. There were no major changes to the information within the document, but the contact details of the specialists have been updated.

Approved

The Committee approved the reviewed guideline for Naltrexone.

Agreed action: -

- The guideline would be shared with LMC for information.

CA

172.2 Amisulpride Shared Care Guidelines

The Amisulpride Shared Care Guideline has been reviewed and updated.

Approved

The Committee approved the reviewed guideline for Amisulpride subject to the inclusion of pregablin in the interaction section on page 3.

SH

Agreed action: -

- The final version would be emailed to the Medicines Management Pharmacist, Barnsley CCG.
- The updated guideline would be shared with LMC for information.

SH
CA

APC 16/173 NEW PRODUCT APPLICATION LOG

There were 2 new product applications being considered by the Committee today and a further 2 new product applications on the log awaiting consideration.

**APC 16/174 NEW PRODUCT APPLICATIONS
174.1**

Alprostadil cream (Vitaros®)

New product application, independent review and declaration of interest received and noted. There was no conflict of interest to note from the applicant.

Approved

After discussion and considering the evidence presented in the independent review, Alprostadil Cream (Vitaros®) was approved second line with the same traffic light status as Caverject and Muse.

Agreed action

- The Medicines Management Pharmacist, Barnsley CCG to check the traffic light status of Caverject and Muse
- Formulary to be updated accordingly
- The Lead Pharmacist, BHNFT to feedback the Committee's decision to the applicant.

CA
CA
GT

Post meeting note: Caverject and Muse both have an Amber-G traffic light status, therefore, Alprostadil cream (Vitaros®) is to be given an Amber-G traffic light status too.

174.2 Briviact ® (brivaracetam)

New product application, independent review and declaration of interest (nothing to declare) received and noted.

Approved

After discussion and considering the evidence presented in the independent review, Briviact ® (brivaracetam) was approved 5th line with a traffic light classification Red.

Agreed action

- Formulary to be updated accordingly
- Review in one year and audit line of therapy used

CA
CL/CA

APC 16/175 BARNSELYAPCREPORT@NHS.NET FEEDBACK

The report was received and noted by the Committee.

There were 4 new incidents reported and these would be reported to APC Reporting and investigated.

Agreed actions

- In relation to the issues raised with a community pharmacy,

	it was agreed that the Lead Pharmacist, BHNFT would share any details and correspondence, including the impact on the patient, with the Head of Medicines Optimisation, Barnsley CCG	GT
	<ul style="list-style-type: none"> • The Head of Medicines Optimisation, Barnsley CCG to write a letter of complaint to the pharmacy, copied to the Community Pharmacist • In relation to an issue where a GP surgery was checking the combination of antiplatelet and anticoagulant when information had already been included on the D1, it was agreed that the details would be shared with Dr Ghani and the MMT, Barnsley CCG to investigate and follow up with the practice. • BAPC16/09/05 has been investigated and can now be closed 	CL GT MG/CL/CA NB
APC 16/176	NEW NICE TECHNOLOGY APPRAISALS – AUGUST 2016	
176.1	<u>Feedback from BHNFT Clinical Guidelines and Policy Group</u> The Lead Pharmacist, BHNFT confirmed that the following NICE TA was applicable for use at BHNFT: -	
	<ul style="list-style-type: none"> • TA404 Degarelix for treating advanced hormone-dependent prostate cancer (red traffic light classification) 	CA
	Awaiting feedback for the following NICE TAs: -	GT
	<ul style="list-style-type: none"> • TA391 Re-issued (replaces TA255) Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel • TA401 Bosutinib for previously treated chronic myeloid leukaemia • TA402 Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin • TA403 Ramucirumab for previously treated locally advanced or metastatic non-smallcell lung cancer • TA405 Trifluridine–tipiracil for previously treated metastatic colorectal cancer 	
176.2	<u>Feedback from SWYPFT NICE Group</u> There were no key points to feedback to the APC.	
APC 16/177	FEEDBACK FROM THE MEDICINES MANAGEMENT GROUPS	
177.1	<u>Primary Care Quality & Cost Effective Prescribing Group</u> The next meeting was planned for 15 th September 2016.	
177.2	<u>BHNFT</u> The next meeting was planned for 15 th September 2016.	
177.3	<u>SWYPFT Drugs & Therapeutics Committee (D&TC)</u> The D&TC had looked at the NICE Guidance for dementia drugs which suggests that GPs could prescribe if specialist area.	

SWYPFT D1 template to be trialled in Barnsley as a paper copy.

Agreed action

- Chief Pharmacist, SWYPFT to check with the Lead Pharmacist, SWYPFT that this has been considered and endorsed by the LMC.

JR/SH

APC 16/178 ISSUES FOR ESCALATION TO THE QUALITY & PATIENT SAFETY COMMITTEE

Agreed action

- It was agreed to escalate the APG Regional Consultation and Epipen switch discussion to the Quality & Patient Safety Committee

CL

APC 16/179 HORIZON SCANNING DOCUMENT – AUGUST 2016

The Committee agreed to classify the new products as follows on the traffic light list (TLL): -

CA

Budesonide/formoterol 200 micrograms/6 micrograms pressurised inhalation suspension MDI (Symbicort[®], AstraZeneca) – **PROVISIONAL GREY**

Bazedoxifene/ conjugated oestrogens 0.45 mg/20 mg modified-release tablets (Duavive[®], Merck Sharp & Dohme) – **PROVISIONAL GREY**

Infliximab (biosimilar) 100 mg powder for concentrate for solution for infusion (Flixabi[®], Biogen Idec) – **ALREADY RED ON TLL**

Salbutamol/ ipratropium 0.5mg/2.5mg per 2.5 ml nebuliser Solution (Salipraneb[®], Actavis UK) – **PROVISIONAL GREY**

Asparaginase 10,000 U powder for concentrate for solution for infusion (Spectrila[®], medac GmbH) – **PROVISIONAL RED**

Eftrenonacog alfa 250 IU, 500 IU, 1000 IU, 2000 IU and 3000 IU powder and solvent for solution for injection (Alprolix[®], Swedish Orphan Biovitrum) – **PROVISIONAL RED**

Brinzolamide (generic) 10mg/mL eye drops (Brinzolamide, Actavis) – **ALREADY GREEN ON TLL**

Cefuroxime 50 mg powder for solution for intracameral injection (Ximaract[®], Bausch & Lomb U.K) – **PROVISIONAL RED**

Desloratadine (generic) 0.5mg/ml oral solution (Desloratadine, Actavis) – **ALREADY GREEN ON TLL**

Sofosbuvir/velpatasvir 400 mg/100 mg film-coated tablets (Epclusa[®], Gilead Sciences) – **ALREADY RED ON TLL**

Gemcitabine (generic) 10 mg/ml, solution for infusion (Gemcitabine, Ranbaxy) – **ALREADY RED ON TLL**

Bendamustine (generic) 2.5mg/ml powder for concentrate for solution for infusion (Bendamustine, Zentiva) – **ALREADY RED ON TLL**

Trifluridine/tipiracil 15 mg/6.14 mg and 20 mg/8.19 mg film-coated tablets (Lonsurf[®], Servier Laboratories) – **ALREADY RED ON TLL**

Ritonavir 100 mg powder for oral suspension (Norvir[®], AbbVie) – **ALREADY RED ON TLL**

Human normal immunoglobulin 100 mg/ml solution for infusion (Panzyga[®], Octapharma) – **ALREADY RED ON TLL**

Voriconazole (generic) 50 mg, 200 mg film-coated tablets (Voriconazole, Accord Healthcare) 200 mg powder for solution for

infusion (Voriconazole, Panpharma UK) 50 mg, 200 mg film-coated tablets and 200 mg powder for solution for infusion

(Voriconazole, Pfizer) – **ALREADY RED ON TLL**

Irinotecan (generic) 20 mg/ml Concentrate for Solution for Infusion (Irinotecan, Accord Healthcare) – **ALREADY PROVISIONAL RED ON TLL**

Fosfomycin 3 g granules for oral solution (Monuril[®], Profile Pharma) – **ALREADY RED ON TLL**

Human coagulation factor X 250 IU & 500 IU powder and solvent for solution for injection (Coagadex[®]▼, Bio Products Laboratory) – **PROVISIONAL RED**

Paliperidone 175 mg, 263 mg, 350 mg & 525 mg prolonged release suspension for injection (Trevicta[®], Janssen-Cilag) – **ALREADY RED ON TLL**

APC 16/180 MHRA DRUG SAFETY UPDATE – AUGUST 2016

The Committee received and noted the August 2016 MHRA Drug Safety Update. The alert is detailed below: -

1. Riociguat (Adempas): not for use in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias
Patients with pulmonary hypertension associated with idiopathic interstitial pneumonias should not be treated with riociguat in light of interim results from a recently terminated study.

APC 16/181 SOUTH YORKSHIRE AREA PRESCRIBING COMMITTEE MINUTES

The minutes from the joint Rotherham NHS Foundation Trust Drug and Therapeutics Group and NHS Rotherham APC (6th January 2016, 3rd February 2016, 2nd March 2016, 4th May 2016 and 1st June 2016) were received for information.

The NHS Sheffield CCG APG minutes (16th June 2016) were received for information.

The NHS Doncaster & Bassetlaw CCG APC meeting (28th July 2016) were received and noted.

APC 16/182 ANY OTHER BUSINESS

182.1

Doriann Bailey – Pastures New

Doriann Bailey, Interim Head of Quality for Primary Care was thanked for her contribution, help and support and Committee wished her all the best for her future.

182.2

Clinical Trial

GP member (JM) informed the Committee that there was a clinical trial beginning which involved treating children with Domperidone gastroenteritis, for 3 days. It was agreed that further information could be obtained and included within a newsletter article to raise awareness.

CL

182.3

Proposed 2017 meeting dates

Approved, avoiding the planned BEST meeting dates.

Agreed action

- Updated meeting schedule to be circulated.

NB

APC 16/183 DATE AND TIME OF THE NEXT MEETING

The time and date of the next meeting was confirmed as Wednesday, 12th October 2016 at 12.30 pm in the Boardroom, Hilder House.

ADOPTED